GLP-1 Collective

Policy Tracker · Patient Lens · July 11, 2026

A dozen legal cases now argue Novo Nordisk hid its own pricing math

Court filings claim the company knew what was driving costs up and chose not to say so publicly.

Nothing new was filed in the last day. These are the 11 most recent developments affecting GLP-1 access that this tracker has not covered yet, across 3 categories. Each entry links to the full record.

## Coverage and cost

**[Medicare now covers implanted glucose monitors](/fda/cms-lcd-38686)**.

## FDA and safety

**[FDA approves Wegovy HD and expanded dosing for weight loss](/fda/fda-approval-nda215256-suppl-25)**.

**[FDA expands Wegovy's approved uses](/fda/fda-approval-nda218316-suppl-7)**.

## Courts and enforcement

**[Lawsuit claims Novo Nordisk hid real reason for high GLP-1 prices](/lawsuits/cl-73563769)**.

**[Patient sues Eli Lilly over GLP-1 drug marketing](/lawsuits/cl-73562939)**.

**[Patient sues Novo Nordisk over Ozempic pricing and access](/lawsuits/cl-73561826)**.

**[Currie v. Eli Lilly: GLP-1 lawsuit still in court](/lawsuits/cl-73555745)**.

**[Patient sues Novo Nordisk over Ozempic and Wegovy pricing](/lawsuits/cl-73554877)**.

**[Johnson v. Novo Nordisk: pricing lawsuit still in court](/lawsuits/cl-73554159)**.

**[Patients sue Novo Nordisk over insulin price fixing](/lawsuits/cl-73552994)**.

**[Pricing lawsuit against Novo Nordisk moves forward](/lawsuits/cl-73552908)**.

34 further items in this category were tracked today and are listed on the site.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.